1 | median | 30,396 |
2 | mean/median | 15 |
3 | 5-34 | 11 |
4 | i-d | 10 |
5 | polylens | 10 |
6 | zenaida | 9 |
7 | icrs-ii | 6 |
8 | hpqt | 5 |
9 | lock-out | 5 |
10 | caregiver-perceived | 4 |
11 | sixteen-week | 4 |
12 | todos | 4 |
13 | 1987/88 | 3 |
14 | chiralcel | 3 |
15 | dtn | 3 |
16 | elevate-timi | 3 |
17 | ldl-ivb | 3 |
18 | occlusion-free | 3 |
19 | rcmecs | 3 |
20 | re-trace™ | 3 |
21 | teg-hk | 3 |
22 | tlr-free | 3 |
23 | tst/high | 3 |
24 | ≥1-year | 3 |
25 | ≥12-month | 3 |
26 | 41-kd | 2 |
27 | 6-10-year | 2 |
28 | abolute | 2 |
29 | acupunc- | 2 |
30 | ar-a | 2 |
31 | atrial/total | 2 |
32 | cdah | 2 |
33 | howse | 2 |
34 | iia-mvo | 2 |
35 | irc-assessed | 2 |
36 | jelly-roll | 2 |
37 | low-to-moderate-intensity | 2 |
38 | musculocutaneus | 2 |
39 | nuclisens | 2 |
40 | per-client | 2 |
41 | post-occupational | 2 |
42 | prothrombine | 2 |
43 | psidii | 2 |
44 | quality-of-life-adjusted | 2 |
45 | self-timed | 2 |
46 | three-cusped | 2 |
47 | tri-retinol | 2 |
48 | tst/low | 2 |
49 | two-cusped | 2 |
50 | vasera | 2 |
51 | year-2007 | 2 |
52 | ∠tq | 2 |
53 | ≤2-year | 2 |
54 | 'natal | 1 |
55 | 0.2-ms | 1 |
56 | 0.3/1,000 | 1 |
57 | 1.2-day | 1 |
58 | 1/mean | 1 |
59 | 100xtransit | 1 |
60 | 13-s | 1 |
61 | 150-second | 1 |
62 | 16-bp | 1 |
63 | 4+scan | 1 |
64 | 44,487 | 1 |
65 | 6-/12-month | 1 |
66 | 6.736-0.566 | 1 |
67 | =deceleration | 1 |
68 | atg14-containing | 1 |
69 | broad/serious | 1 |
70 | c_1761.1745 | 1 |
71 | chymase-dependent | 1 |
72 | clinical-failure-free | 1 |
73 | door-to-device | 1 |
74 | door-to-thrombolysis | 1 |
75 | dose-targeted | 1 |
76 | everolimusprolonged | 1 |
77 | fibrezyme | 1 |
78 | fimasartan-treated | 1 |
79 | group×testing | 1 |
80 | half-value | 1 |
81 | hrqol-adjusted | 1 |
82 | laryngo-esophageal | 1 |
83 | lif-detector-compatible | 1 |
84 | log-intact | 1 |
85 | mean-centered | 1 |
86 | niemann | 1 |
87 | or=3-month | 1 |
88 | plm/h | 1 |
89 | postdilutional | 1 |
90 | roc-optimal | 1 |
91 | taiping | 1 |
92 | tenstem | 1 |
93 | thirty-six-week | 1 |
94 | trans-permethrin | 1 |
95 | xanthan-based | 1 |
96 | ∼ms | 1 |
97 | ≥34weeks | 1 |
1 | 'natal | 1 |
2 | 0.2-ms | 1 |
3 | 0.3/1,000 | 1 |
4 | 1.2-day | 1 |
5 | 1/mean | 1 |
6 | 100xtransit | 1 |
7 | 13-s | 1 |
8 | 150-second | 1 |
9 | 16-bp | 1 |
10 | 1987/88 | 3 |
11 | 4+scan | 1 |
12 | 41-kd | 2 |
13 | 44,487 | 1 |
14 | 5-34 | 11 |
15 | 6-/12-month | 1 |
16 | 6-10-year | 2 |
17 | 6.736-0.566 | 1 |
18 | =deceleration | 1 |
19 | abolute | 2 |
20 | acupunc- | 2 |
21 | ar-a | 2 |
22 | atg14-containing | 1 |
23 | atrial/total | 2 |
24 | broad/serious | 1 |
25 | c_1761.1745 | 1 |
26 | caregiver-perceived | 4 |
27 | cdah | 2 |
28 | chiralcel | 3 |
29 | chymase-dependent | 1 |
30 | clinical-failure-free | 1 |
31 | door-to-device | 1 |
32 | door-to-thrombolysis | 1 |
33 | dose-targeted | 1 |
34 | dtn | 3 |
35 | elevate-timi | 3 |
36 | everolimusprolonged | 1 |
37 | fibrezyme | 1 |
38 | fimasartan-treated | 1 |
39 | group×testing | 1 |
40 | half-value | 1 |
41 | howse | 2 |
42 | hpqt | 5 |
43 | hrqol-adjusted | 1 |
44 | i-d | 10 |
45 | icrs-ii | 6 |
46 | iia-mvo | 2 |
47 | irc-assessed | 2 |
48 | jelly-roll | 2 |
49 | laryngo-esophageal | 1 |
50 | ldl-ivb | 3 |
51 | lif-detector-compatible | 1 |
52 | lock-out | 5 |
53 | log-intact | 1 |
54 | low-to-moderate-intensity | 2 |
55 | mean-centered | 1 |
56 | mean/median | 15 |
57 | median | 30,396 |
58 | musculocutaneus | 2 |
59 | niemann | 1 |
60 | nuclisens | 2 |
61 | occlusion-free | 3 |
62 | or=3-month | 1 |
63 | per-client | 2 |
64 | plm/h | 1 |
65 | polylens | 10 |
66 | post-occupational | 2 |
67 | postdilutional | 1 |
68 | prothrombine | 2 |
69 | psidii | 2 |
70 | quality-of-life-adjusted | 2 |
71 | rcmecs | 3 |
72 | re-trace™ | 3 |
73 | roc-optimal | 1 |
74 | self-timed | 2 |
75 | sixteen-week | 4 |
76 | taiping | 1 |
77 | teg-hk | 3 |
78 | tenstem | 1 |
79 | thirty-six-week | 1 |
80 | three-cusped | 2 |
81 | tlr-free | 3 |
82 | todos | 4 |
83 | trans-permethrin | 1 |
84 | tri-retinol | 2 |
85 | tst/high | 3 |
86 | tst/low | 2 |
87 | two-cusped | 2 |
88 | vasera | 2 |
89 | xanthan-based | 1 |
90 | year-2007 | 2 |
91 | zenaida | 9 |
92 | ∠tq | 2 |
93 | ∼ms | 1 |
94 | ≤2-year | 2 |
95 | ≥1-year | 3 |
96 | ≥12-month | 3 |
97 | ≥34weeks | 1 |
1 | acupunc- | 2 |
2 | 0.3/1,000 | 1 |
3 | 5-34 | 11 |
4 | c_1761.1745 | 1 |
5 | 6.736-0.566 | 1 |
6 | year-2007 | 2 |
7 | 44,487 | 1 |
8 | 1987/88 | 3 |
9 | ar-a | 2 |
10 | zenaida | 9 |
11 | vasera | 2 |
12 | ldl-ivb | 3 |
13 | i-d | 10 |
14 | everolimusprolonged | 1 |
15 | self-timed | 2 |
16 | three-cusped | 2 |
17 | two-cusped | 2 |
18 | mean-centered | 1 |
19 | xanthan-based | 1 |
20 | irc-assessed | 2 |
21 | fimasartan-treated | 1 |
22 | dose-targeted | 1 |
23 | quality-of-life-adjusted | 2 |
24 | hrqol-adjusted | 1 |
25 | caregiver-perceived | 4 |
26 | 41-kd | 2 |
27 | 150-second | 1 |
28 | door-to-device | 1 |
29 | clinical-failure-free | 1 |
30 | occlusion-free | 3 |
31 | tlr-free | 3 |
32 | lif-detector-compatible | 1 |
33 | fibrezyme | 1 |
34 | prothrombine | 2 |
35 | howse | 2 |
36 | abolute | 2 |
37 | half-value | 1 |
38 | atg14-containing | 1 |
39 | taiping | 1 |
40 | group×testing | 1 |
41 | plm/h | 1 |
42 | cdah | 2 |
43 | tst/high | 3 |
44 | 6-/12-month | 1 |
45 | ≥12-month | 3 |
46 | or=3-month | 1 |
47 | icrs-ii | 6 |
48 | psidii | 2 |
49 | elevate-timi | 3 |
50 | sixteen-week | 4 |
51 | thirty-six-week | 1 |
52 | teg-hk | 3 |
53 | laryngo-esophageal | 1 |
54 | roc-optimal | 1 |
55 | post-occupational | 2 |
56 | postdilutional | 1 |
57 | 'natal | 1 |
58 | atrial/total | 2 |
59 | chiralcel | 3 |
60 | jelly-roll | 2 |
61 | tri-retinol | 2 |
62 | tenstem | 1 |
63 | 4+scan | 1 |
64 | 1/mean | 1 |
65 | median | 30,396 |
66 | mean/median | 15 |
67 | trans-permethrin | 1 |
68 | niemann | 1 |
69 | =deceleration | 1 |
70 | dtn | 3 |
71 | iia-mvo | 2 |
72 | 16-bp | 1 |
73 | ∠tq | 2 |
74 | 6-10-year | 2 |
75 | ≥1-year | 3 |
76 | ≤2-year | 2 |
77 | 13-s | 1 |
78 | rcmecs | 3 |
79 | door-to-thrombolysis | 1 |
80 | ≥34weeks | 1 |
81 | 0.2-ms | 1 |
82 | ∼ms | 1 |
83 | polylens | 10 |
84 | nuclisens | 2 |
85 | todos | 4 |
86 | musculocutaneus | 2 |
87 | broad/serious | 1 |
88 | log-intact | 1 |
89 | 100xtransit | 1 |
90 | chymase-dependent | 1 |
91 | per-client | 2 |
92 | hpqt | 5 |
93 | lock-out | 5 |
94 | tst/low | 2 |
95 | 1.2-day | 1 |
96 | low-to-moderate-intensity | 2 |
97 | re-trace™ | 3 |